Patents Assigned to Intercept Pharmaceuticals, Inc.
-
Patent number: 11807659Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.Type: GrantFiled: April 14, 2022Date of Patent: November 7, 2023Assignee: INTERCEPT PHARMACEUTICALS, INC.Inventors: Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
-
Publication number: 20230057232Abstract: The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereofType: ApplicationFiled: September 7, 2022Publication date: February 23, 2023Applicant: INTERCEPT PHARMACEUTICALS, INC.Inventors: Gabriel GALVIN, Kevin SCHAAB, Matthew YANIK
-
Patent number: 11472831Abstract: The present application relates to isotopically labeled compounds of Formula I and methods of preparation and use thereof.Type: GrantFiled: July 23, 2018Date of Patent: October 18, 2022Assignee: Intercept Pharmaceuticals, Inc.Inventors: Gabriel Galvin, Kevin Schaab, Mathew Yanik
-
Patent number: 11419878Abstract: The present invention provides an NASH therapeutic agent including: an FXR agonist, preferably obeticholic acid or a pharmaceutically acceptable salt thereof; and an ARB or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 27, 2017Date of Patent: August 23, 2022Assignee: Intercept Pharmaceuticals, Inc.Inventors: Tadashi Namisaki, Hitoshi Yoshiji
-
Patent number: 11413295Abstract: The present invention pertains to an oral preparation having exceptional elutability, the oral preparation containing obeticholic acid or a pharmacologically acceptable salt thereof, a water-soluble excipient, a disintegrating agent, and a water-soluble polymer binder, wherein the oral preparation is a quick-release tablet.Type: GrantFiled: March 30, 2017Date of Patent: August 16, 2022Assignee: INTERCEPT PHARMACEUTICALS, INC.Inventors: Mitsuhiro Matono, Tetsuya Hayama
-
Publication number: 20220226350Abstract: The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and a fibrate. Also disclosed is use of the combination for the treatment, amelioration or prevention of an FXR mediated disease or condition, such as primary biliary cholangitis (PBC).Type: ApplicationFiled: May 29, 2020Publication date: July 21, 2022Applicant: Intercept Pharmaceuticals, Inc.Inventors: Leigh A. MACCONELL, Richard PENCEK
-
Patent number: 11345721Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.Type: GrantFiled: September 2, 2020Date of Patent: May 31, 2022Assignee: INTERCEPT PHARMACEUTICALS, INC.Inventors: Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
-
Patent number: 11319337Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.Type: GrantFiled: September 18, 2020Date of Patent: May 3, 2022Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Antimo Gioiello
-
Patent number: 11311557Abstract: The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.Type: GrantFiled: February 5, 2016Date of Patent: April 26, 2022Assignee: Intercept Pharmaceuticals, Inc.Inventors: Mark Pruzanski, Luciano Adorini
-
Patent number: 11072631Abstract: The present invention relates to methods and novel intermediates useful in the preparation of a compound of formula (A) or a pharmaceutically acceptable salt thereof, comprising converting the aldehyde of a compound of formula (B) with a reducing agent to prepare a compound of formula (C) and converting the compound of formula (C) with a sulfating reagent to prepare a compound of formula (A). An objective of the present invention is to provide methods of preparing bile acid derivatives and novel intermediates. A use of the methods and intermediates described relates to the synthesis of bile acid derivatives which activate both FXR and TGR5.Type: GrantFiled: September 23, 2016Date of Patent: July 27, 2021Assignee: Intercept Pharmaceuticals, Inc.Inventors: Kevin Schaab, Paul E. Whitley, Flavio Chavez Lopez, Kayla R. Iorga
-
Patent number: 11066437Abstract: The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof, comprising the step of reacting a compound of formula I-4 with a halogenating reagent to provide a compound of formula I-5aType: GrantFiled: June 22, 2018Date of Patent: July 20, 2021Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Antimo Gioiello, Gabriel Galvin, Ronald D. Lewis, II, Mathew Yanik, Myoung Goo Kim, Frederik Ronald Leusink, Bartjan Koning, Thomas Hensel
-
Patent number: 11034717Abstract: The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1-R10, m, n, p, and are as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.Type: GrantFiled: October 7, 2016Date of Patent: June 15, 2021Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Antimo Gioiello
-
Patent number: 11000532Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.Type: GrantFiled: November 26, 2019Date of Patent: May 11, 2021Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 10987362Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.Type: GrantFiled: December 21, 2018Date of Patent: April 27, 2021Assignee: Intercept Pharmaceuticals, Inc.Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
-
Patent number: 10894054Abstract: The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition, such as NAFLD and NASH, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.Type: GrantFiled: April 6, 2016Date of Patent: January 19, 2021Assignee: Intercept Pharmaceuticals, Inc.Inventors: Mark Pruzanski, Luciano Adorini
-
Patent number: 10815267Abstract: The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.Type: GrantFiled: March 7, 2017Date of Patent: October 27, 2020Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Antimo Gioiello
-
Patent number: 10800807Abstract: The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.Type: GrantFiled: June 16, 2016Date of Patent: October 13, 2020Assignee: Intercept Pharmaceuticals, Inc.Inventors: Roberto Pellicciari, Antimo Gioiello, Antonio Macchiarulo, Francoise Perron-Sierra, Klaus Seedorf
-
Patent number: 10758549Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.Type: GrantFiled: February 11, 2020Date of Patent: September 1, 2020Assignee: Intercept Pharmaceuticals, Inc.Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
-
Patent number: 10751349Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.Type: GrantFiled: January 15, 2019Date of Patent: August 25, 2020Assignee: Intercept Pharmaceuticals, Inc.Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
-
Patent number: RE48286Abstract: The invention relates to compounds of formula (I): wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: GrantFiled: June 21, 2019Date of Patent: October 27, 2020Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari